In a significant clinical achievement, Apollo Cancer Centre, Bannerghatta Road, Bengaluru, successfully treated a 30-year-old woman suffering from gelastic seizures using CyberKnife technology. For nearly 25 years, the patient experienced 30 to 40 uncontrollable laughing episodes every day, despite taking multiple anti-epileptic medications and undergoing extensive neurological evaluations.
However, after receiving CyberKnife treatment, the frequency of her seizures reduced dramatically, marking a major improvement after decades of daily episodes.
Understanding Gelastic Seizures
Gelastic seizures are an extremely rare form of epilepsy, commonly referred to as “laughing seizures.” In this condition, patients experience sudden and uncontrollable bouts of laughter triggered by abnormal brain activity.
Although the disorder typically begins in childhood and is seen more frequently in women, it represents only a very small proportion of epilepsy cases worldwide. In many cases, gelastic seizures are associated with hypothalamic hamartoma, a benign brain tumour. Consequently, the condition is often misdiagnosed and can be difficult to manage using conventional anti-epileptic medications.
CyberKnife Offers Precise, Non-Invasive Treatment
To address the condition, doctors used the CyberKnife system, an advanced robotic radiosurgery technology designed for precise, non-invasive treatment.
CyberKnife continuously tracks tumour motion and automatically adjusts the treatment beam whenever movement occurs. Using real-time imaging and a robotic arm, it delivers radiation with sub-millimetre accuracy. As a result, the radiation targets only the affected area while minimising exposure to surrounding healthy brain tissue.
Importantly, CyberKnife can treat a wide range of cancers, benign tumours, and functional neurological disorders, making it a versatile tool in modern medicine.
Expanding Treatment Options for Neurological Disorders
The success of this case highlights the growing potential of CyberKnife in treating complex neurological conditions. In addition to gelastic seizures, the technology has shown promise in managing disorders such as:
- Parkinson’s disease
- Essential tremor
- Trigeminal neuralgia
- Cervical dystonia
Moreover, CyberKnife offers a non-invasive alternative to traditional surgical procedures, including deep brain stimulation, especially for patients who do not respond to conventional medications.
Experts Highlight Benefits of CyberKnife
As per the press release, Dr. Sridhar P S, Senior Consultant and Lead – CyberKnife at Apollo Cancer Centre, Bengaluru, emphasised the significance of this technology in managing rare neurological conditions.
“At Apollo Cancer Centre, Bengaluru, we constantly push the boundaries of what advanced, non-invasive care can achieve. For patients with rare and complex epilepsy conditions, CyberKnife allows us to precisely target the seizure-triggering area without opening the skull or administering anesthesia. Its high accuracy protects healthy brain tissue, while the treatment itself remains painless, safe, and highly effective. This approach has the potential to transform the quality of life for patients who previously had very limited treatment options.”
Clinical Impact on Patient Recovery
Dr. Gurucharan Adoor, Senior Consultant – Neurology at Apollo Hospitals, Bannerghatta Road, explained that gelastic seizures are among the most difficult forms of epilepsy to diagnose and manage, primarily because of their rarity and unusual presentation.
“In long-standing cases like this, patients often undergo years of treatment with limited response to anti-epileptic drugs. What is particularly encouraging in this case is the sustained reduction in seizure frequency after treatment. Such improvement not only stabilises neurological function but also significantly enhances the patient’s cognitive, emotional, and social well-being. Early diagnosis and access to advanced therapies can dramatically improve outcomes in such complex cases,” he noted.
Dramatic Reduction in Seizure Episodes
Following the CyberKnife procedure, the patient experienced only three seizure episodes throughout the entire year, compared to the 30 daily episodes she had endured for 25 years.
This remarkable outcome demonstrates how advanced medical technologies are transforming the treatment of rare and complex neurological disorders. Furthermore, it offers renewed hope to patients and families who previously had limited therapeutic options.